Future Directions and Unmet Needs in T-ALL

Bijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.

Bijal Shah, MD, MS, an associate member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia (T-ALL) space and what future research aims to examine.

During a session at The NCCN 2022 Annual Congress of Hematologic Malignancies, experts, including Shah, explained initial strategies, various treatment options, and future directions for patients with ALL.

According to Shah, while a lot of progress has been made in the field of ALL over time, a lot of questions remain when treating patients with T-ALL.

Transcription:

0:08 | Using immunotherapies, particularly using T Cells to target cells, has been hard. I think we are trying to find better ways of using molecularly-directed therapy and in some cases, certain kinds of immunotherapies like daratumumab [Darzalex] to try to improve outcomes in a very difficult-to-treat disease.

0:34 | I think the key takeaway for T-ALL is that we are moving slowly to where we were 7 or 8 years ago in B-cell ALL. Now many people recognize that there is a big unmet medical need here. We are starting to see pharmacologists and the academician come together to begin to develop studies, this is a rare disease so often across several centers, to try and address this problem. Again, I am hopeful that the next time we meet, I am talking to you about some incredible advance that is going to shake up what we do in terms of that standard monolithic chemotherapeutic approach for T-ALL.